TNFRSF13C as a Radioligand Therapy Target
TNFRSF13C, TNF receptor superfamily member 13C, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, TNFRSF13C staining is highest in lymphoma (100% of samples positive). Evidence on whether TNFRSF13C internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is TNFRSF13C a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in lymphoma, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
TNFRSF13C expression in cancer
Protein expression of TNFRSF13C across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lymphoma | 0.94 | High | 100% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.
Is TNFRSF13C internalized?
Uncertain. Insufficient literature found.
TNFRSF13C clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for TNFRSF13C yet. Search ClinicalTrials.gov for TNFRSF13C trials.
TNFRSF13C normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See TNFRSF13C in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
TNFRSF13C gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.07 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lymphoma radioligand targets
c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD45 (PTPRC) · CD19 · SSTR2 · STEAP2 · CD22
See all radioligand therapy targets in lymphoma.
See how TNFRSF13C ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.